Virpax Pharmaceuticals Valuation
| VRPXDelisted Stock | USD 0.25 0.04 19.05% |
Virpax Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Virpax Pharmaceuticals from inspecting the company fundamentals such as Shares Owned By Institutions of 0.41 %, return on equity of -23.65, and Shares Outstanding of 1.24 M as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Virpax Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Virpax Pharmaceuticals is based on 3 months time horizon. Increasing Virpax Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Virpax Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Virpax Pink Sheet. However, Virpax Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.25 | Real 0.24 | Hype 0.25 | Naive 0.34 |
The intrinsic value of Virpax Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Virpax Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Virpax Pharmaceuticals helps investors to forecast how Virpax pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Virpax Pharmaceuticals more accurately as focusing exclusively on Virpax Pharmaceuticals' fundamentals will not take into account other important factors: Virpax Pharmaceuticals Total Value Analysis
Virpax Pharmaceuticals is at this time projected to have valuation of (1.21 M) with market capitalization of 831.85 K, debt of 2.47 B, and cash on hands of 26.06 M. The negative valuation of Virpax Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Virpax Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.21 M) | 831.85 K | 2.47 B | 26.06 M |
Virpax Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Virpax is to check how much profit was generated for every dollar of assets it reports. Virpax Pharmaceuticals has a negative utilization of assets of -1.35 %, losing $0.0135 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Virpax Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Virpax Pharmaceuticals Ownership Allocation
About 98.64 % of Virpax Pharmaceuticals outstanding shares are held by general public with 0.96 (%) owned by insiders and only 0.41 % by institutional holders.Virpax Pharmaceuticals Profitability Analysis
Net Loss for the year was (12.07 B) with profit before overhead, payroll, taxes, and interest of 0.About Virpax Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Virpax Pharmaceuticals. We calculate exposure to Virpax Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Virpax Pharmaceuticals's related companies.Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Virpax Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.
8 Steps to conduct Virpax Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Virpax Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Virpax Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Virpax Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Virpax Pharmaceuticals' revenue streams: Identify Virpax Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Virpax Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Virpax Pharmaceuticals' growth potential: Evaluate Virpax Pharmaceuticals' management, business model, and growth potential.
- Determine Virpax Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Virpax Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Virpax Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 4.3 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Virpax Pink Sheet
If you are still planning to invest in Virpax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virpax Pharmaceuticals' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |